by Cal Strode | Nov 2, 2026
Back in August 2016, Signals celebrated ten years of induced pluripotent stem cells (iPSCs) by hosting its first-ever blog carnival, in which contributors each wrote posts answering the same question: With useful treatments for diseases like heart failure and diabetes...
by Stacey Johnson | Oct 2, 2026
As someone who regularly consumes broadcast and print news, I can confirm that coverage, analysis and opinion pieces on artificial intelligence (AI) are everywhere. AI is coming for our jobs, but it will also happily recommend a new one for us. AI has the potential to...
by Stacey Johnson | Mar 30, 2026
Although it’s wrapping up, March is National Engineering Month in Canada. This is a great time to ask: Who is building the future of engineering in Canada, and who is still waiting for a seat at the table? Increasingly, that future doesn’t just look like roads and...
by Cal Strode | Jan 28, 2026
This year marks the fourth consecutive time I’ve covered the Alliance for Regenerative Medicine’s (ARM) State of the Industry briefing for Signals, and I’ve enjoyed tracking how the cell and gene therapy sector has evolved in real time. In 2023 and 2024, the briefings...
by Stacey Johnson | Jan 9, 2026
It’s that time of year when we look back at what was popular on Signals over the past 12 months, according to views. I am always curious to see what you are reading and perhaps you are as well? As we head into our 14th year of publishing Signals, I’m very aware of all...
by Stacey Johnson | Dec 25, 2025
2025 is almost behind us. Are the years speeding up, or is it just me? I’d like to wish all of you a very Merry Christmas, if you celebrate, and a Happy New Year. This year, Signals bloggers, past and present, have an additional reason to be excited. CCRM has been...
Comments